This segment focuses on the research, development, and clinical evaluation of novel therapies for rare genetic mitochondrial diseases. The primary focus is on REN001 (mavodelpar), a selective peroxisome proliferator-activated receptor delta (PPARδ) agonist. Research and development activities include preclinical studies, Phase 1b and Phase IIb clinical trials, and formulation development. Technologies and methodologies include PPARδ agonism, metabolic pathway modulation, and biomarker analysis. The therapeutic areas covered are primary mitochondrial myopathies (PMM) and long-chain fatty acid oxidation disorders (LC-FAOD). The goal is to improve the quality of life for patients suffering from these debilitating conditions by addressing the underlying metabolic defects. Market positioning is centered on addressing unmet medical needs in the rare disease space. Competitive advantages include a targeted mechanism of action and potential for disease modification. Future opportunities include expanding the clinical program and exploring additional indications. Regulatory and clinical aspects involve interactions with the FDA and other regulatory bodies to ensure compliance and facilitate drug approval. Partnerships and collaborations are essential for clinical trial execution and commercialization.